OPKO Health (OPK) CEO Purchases $202,520.00 in Stock

OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 61,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The shares were purchased at an average price of $3.32 per share, for a total transaction of $202,520.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $10,188,917.32. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, April 5th, Phillip Md Et Al Frost purchased 10,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $32,500.00.
  • On Tuesday, April 3rd, Phillip Md Et Al Frost purchased 153,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.00 per share, with a total value of $459,000.00.
  • On Wednesday, March 28th, Phillip Md Et Al Frost purchased 80,000 shares of OPKO Health stock. The stock was acquired at an average cost of $3.07 per share, with a total value of $245,600.00.
  • On Monday, March 26th, Phillip Md Et Al Frost acquired 26,000 shares of OPKO Health stock. The shares were purchased at an average price of $3.19 per share, with a total value of $82,940.00.
  • On Friday, March 23rd, Phillip Md Et Al Frost acquired 25,000 shares of OPKO Health stock. The shares were purchased at an average price of $3.27 per share, with a total value of $81,750.00.
  • On Wednesday, March 21st, Phillip Md Et Al Frost acquired 30,000 shares of OPKO Health stock. The shares were purchased at an average price of $3.38 per share, with a total value of $101,400.00.
  • On Monday, March 19th, Phillip Md Et Al Frost acquired 40,000 shares of OPKO Health stock. The shares were purchased at an average price of $3.51 per share, with a total value of $140,400.00.
  • On Monday, March 12th, Phillip Md Et Al Frost acquired 25,000 shares of OPKO Health stock. The shares were purchased at an average price of $3.48 per share, with a total value of $87,000.00.
  • On Wednesday, March 7th, Phillip Md Et Al Frost acquired 75,000 shares of OPKO Health stock. The shares were purchased at an average price of $3.29 per share, with a total value of $246,750.00.
  • On Friday, March 2nd, Phillip Md Et Al Frost acquired 364,800 shares of OPKO Health stock. The shares were purchased at an average price of $2.94 per share, with a total value of $1,072,512.00.

NASDAQ:OPK opened at $3.07 on Monday. OPKO Health has a 1-year low of $2.66 and a 1-year high of $7.90. The firm has a market capitalization of $1,717.58, a PE ratio of -10.59 and a beta of 1.56. The company has a current ratio of 1.14, a quick ratio of 0.98 and a debt-to-equity ratio of 0.02.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). The firm had revenue of $193.70 million for the quarter, compared to analysts’ expectations of $307.44 million. OPKO Health had a negative return on equity of 7.87% and a negative net margin of 28.93%. research analysts predict that OPKO Health will post -0.48 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in shares of OPKO Health by 127.2% in the third quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after buying an additional 2,241,103 shares in the last quarter. Geode Capital Management LLC increased its position in OPKO Health by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 3,429,271 shares of the biotechnology company’s stock worth $16,803,000 after purchasing an additional 78,477 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in OPKO Health by 42.0% during the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 2,051,732 shares of the biotechnology company’s stock worth $10,053,000 after purchasing an additional 606,422 shares during the last quarter. IFP Advisors Inc increased its position in OPKO Health by 37.1% during the fourth quarter. IFP Advisors Inc now owns 1,963,601 shares of the biotechnology company’s stock worth $9,622,000 after purchasing an additional 531,088 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in OPKO Health by 43.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock worth $10,746,000 after purchasing an additional 471,256 shares during the last quarter. 23.39% of the stock is currently owned by institutional investors and hedge funds.

OPK has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $20.00 price target on shares of OPKO Health and gave the company a “buy” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. BidaskClub upgraded shares of OPKO Health from a “strong sell” rating to a “sell” rating in a research note on Friday, January 26th. ValuEngine lowered shares of OPKO Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Finally, JPMorgan Chase lowered shares of OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 price objective on the stock. in a research note on Friday, March 2nd. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. OPKO Health presently has a consensus rating of “Hold” and a consensus target price of $11.29.

ILLEGAL ACTIVITY WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/09/opko-health-inc-opk-ceo-phillip-md-et-al-frost-buys-61000-shares-of-stock.html.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply